Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Individual factors such as baseline gut sensitivity, concurrent medications (especially metformin, which can independently cause diarrhea), and pre-existing conditions like irritable bowel syndrome significantly influence whether diarrhea develops and its severity
Studies show that patients who titrate slowly over 8 to 12 weeks experience significantly milder gastrointestinal symptoms compared to those who rapidly increase doses
Prausnitz MR, Langer R
Keep a symptom diary documenting stool frequency, consistency (using the Bristol Stool Chart), timing relative to injections and meals, and dietary intake
Another promising direction involves mucoadhesive nanocarriers that anchor to intestinal epithelium and release GLP-1 analogs in a site-specific manner, minimizing systemic degradation [35]
